| Drug General Information |
| Drug ID |
D02OZK
|
| Former ID |
DNCL002475
|
| Drug Name |
Obatoclax
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 2 |
[1]
|
|---|
| Company |
Cephalon
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H19N3O
|
| Canonical SMILES |
CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C
|
| InChI |
1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21,23H,1-3H3/b18-17-,19-10-
|
| InChIKey |
CVCLJVVBHYOXDC-IAZSKANUSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
|
| Drug Resistance Mutation (DRM) |
| DRM |
DRM Info
|
| Target and Pathway |
| Target(s) |
Apoptosis regulator Bcl-2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Antiapoptotic protein BCL-XL |
Target Info |
Inhibitor |
[1]
|
| Induced myeloid leukemia cell differentiation protein Mcl-1 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Focal adhesion
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Prostate cancer
|
|
Small cell lung cancerhsa04014:Ras signaling pathway
|
|
Jak-STAT signaling pathway
|
|
HTLV-I infection
|
|
Transcriptional misregulation in cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancerhsa04151:PI3K-Akt signaling pathway
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
TSLP Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Notch Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
Oxidative stress response
|
|
CCKR signaling map STP00006:Apoptosis signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
Ceramide signaling pathway
|
|
Direct p53 effectors
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
ATF-2 transcription factor network
|
|
C-MYB transcription factor network
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Validated targets of C-MYC transcriptional repressionil2_pi3kpathway:IL2 signaling events mediated by PI3K
|
|
IL3-mediated signaling events
|
|
IL2 signaling events mediated by STAT5e2f_pathway:E2F transcription factor network
|
|
IL6-mediated signaling events
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
Activation of BAD and translocation to mitochondria
|
|
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasomeR-HSA-111453:BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
|
|
The NLRP1 inflammasome
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
IL-2 Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Focal Adhesion
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
Apoptosis
|
|
Nanoparticle triggered autophagic cell death
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Corticotropin-releasing hormone
|
|
Interleukin-11 Signaling Pathway
|
|
Prostate Cancer
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Intrinsic Pathway for Apoptosis
|
|
Apoptosis Modulation and Signaling
|
|
TP53 Network
|
|
Influenza A virus infection
|
|
IL-5 Signaling PathwayWP364:IL-6 signaling pathway
|
|
TNF alpha Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Leptin signaling pathway
|
|
Apoptosis Modulation and SignalingWP254:Apoptosis
|
| References |
| REF 1 | Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. |
|---|
